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In addition to the central nervous system, 
vasoactive intestinal peptide (VIP) containing nerves 
have been described throughout the female genital tract. 
VIP is reported to be produced by nerves fibers 
innervating follicles at all stages of development in 
rodents. There is growing evidence that VIP and their 
receptors play important roles in the local regulat ion of 
ovarian physiology mostly through cAMP pathway.  It 
has been reported that VIP regulates the ovarian follicle 
survival and growth, oocyte maturation, ovulation and 
steroidogenesis. Studies also demonstrated that VIP 
inhibits apoptosis of rat follicles and is an important 
factor for the growth of preantral follicles enclosed in 
caprine ovarian tissue. Even though the addition of VIP 
to the culture medium did not improve in vitro 
maturation and fert ilization of oocytes, it has been 
shown to stimulate ovulation in perfused rat ovaries. 
VIP is also involved in the regulation of steroidogenic 
activity. Therefore, this review aims to summarize 
current data on the importance of VIP on ovarian 
physiology. 
 





Ovarian activ ity is regulated not only by 
gonadotropins and steroids, but also by a number of 
neural inputs and paracrine regulatory mechanisms. The 
mammalian ovary is innervated by extrinsic nerves, 
which are both catecholaminerg ic and peptidergic in 
nature (Burden, 1985; Ojeda and Lara, 1989; Ojeda et 
al., 1989). Peptidergic innervation of the ovary was 
verified, among other ways, by the presence of vasoactive 
intestinal peptide (VIP) (Ahmed et al., 1986). 
In addition to the central nervous system, VIP 
containing nerves have been described throughout the 
human female genital tract being most abundant in the 
vagina, cervix and clitoris and less numerous in the 
uterine body, oviduct and ovary (Ottesen and 
Fahrenkrug, 1995), which suggests that such peptides 
may not play an  exclusively neuroendocrine role. The 
lack o f rad ioimmunoassayable VIP levels following the 
transection of the ovarian nerves indicates that ovarian 
VIP derives mostly from extrinsic innervation of the 
gland (Dees et al., 1986; Advis et al., 1989). The VIP 
immunoreactive nerve fibers reach the ovary via the 
suspensory ligament (Dees et al., 1986) and are located 
around blood vessels, in the interstitial g land and in the 
follicu lar wall of the ovary (Kannisto et al., 1986; 
Ahmed et al., 1986). However, the local ovarian 
synthesis of the peptide is suggested by the ability to 
detect VIP mRNA within rat ovarian t issue (Gozes and 
Tsafriri, 1986; Bruno et al., 2011; State University of 
Ceará, Fortaleza, Brazil; personal communication). There 
is growing evidence that VIP plays an important role in 
the female reproductive system by acting as a potential 
local regulator of ovarian physiology, such as regulation 
of steroidogenesis, cAMP accumulation, plasminogen 
activator production and oocyte maturation (Ahmed et 
al., 1986; Tornell et al., 1988; Johnson and Tilly, 1988). 
This review will focus on the role of VIP and its 
receptors in ovarian physiology. 
 
Expression of VIP and its receptors in the ovary 
 
VIP is a member of the structurally related 
neuropeptide family including pituitary adenylate 
cyclase-activating polypeptide (PACAP)/secretin/ 
glucagons (Miyata et al., 1989; Arimura, 1992; Gozes et 
al., 1999). VIP and PACAP act by binding to three 
types of G protein-coupled VIP/PACAP receptors: 
PAC1-R, which exhib its a 300- to 1000-fold h igher 
affinity for PACAP than for VIP (Harmar et al., 1998); 
VPAC1-R and VPAC2-R, which exh ibit similar 
affinities for the two neuropeptides (Lutz et al., 1993).  
Harikumar et al., (2006) demonstrated, by 
using biophysical methods, that VPAC1-R and VPAC2-
R formed constitutive homo- and heterodimers. Langer 
et al. (2006) studied the pharmacological properties of 
VPAC1-R and VPAC2-R co-expressed in Chinese-
hamster ovary cells, and they confirmed by co-
immunoprecip itation that the two receptors did interact 
and found that receptor co-expression did not modify 
VIP or selective agonist affinities. Similarly, the 
potency of agonists to stimulate adenylate cyclase 
activity was unaffected, suggesting that the properties of 
the selective ligands that were established in cell lines 
expressing a single population of VIP receptors were 
valid in cells expressing both receptors. Similarly, VIP 
receptor co-expression did not modify receptor 
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internalizat ion and trafficking patterns following VIP or 
selective agonist exposure (Langer et al., 2006). 
In ovaries, VIP is reported to be produced by 
nerve fibers innervating follicles at all stages of 
development in rodent (Ahmed et al., 1986) and avian 
(Johnson et al., 1994) species. Hulshof et al. (1994) 
showed that bovine ovary is innervated by VIP-positive 
nerve fibers, beginning at the onset of follicular 
development and increasing with age. Furthermore, VIP 
and its receptors immunoreactivity has been found in 
close association with the ovarian vasculature (Hulshof 
et al., 1994; Vaccari et al., 2006). 
Despite the presence of mRNA for VIP has 
been detected in ovaries of rats (Gozes and Tsafriri, 
1986), its presence was not observed in mice (Barberi et 
al., 2007). However, in goats, the presence of mRNA 
for VIP was detected in all follicu lar categories 
(primordial, primary, secondary and antral follicles) and 
cellu lar types (granulosa and theca cells) studied; Bruno 
et al., 2011; State University of Ceará, Fortaleza, Brazil; 
personal communicat ion, suggesting a local synthesis of 
this peptide. Furthermore, quantificat ion of mRNA 
demonstrated that secondary follicles had significantly 
higher levels of VIP mRNA compared to the primord ial 
follicle. Granulosa/theca cells from large antral follicles 
had higher levels of VIP mRNA than small antral 
follicles (Bruno et al., 2011; State University of Ceará, 
Fortaleza, Brazil; personal communication). 
Barberi et al. (2007) showed that the 
PACAP/VIP receptors are expressed in mouse 
granulosa cells in vivo. Furthermore, other authors have 
shown that VPAC1-R is the most abundant receptor in 
ovaries from juvenile mice, and that VPAC2-R levels 
are lower, while those of PAC1-R are very low 
(Cecconi et al., 2004). In the rat preovulatory follicles, 
PAC1-R and VPAC2-R are expressed by granulosa 
cells, whereas theca/interstitial cells exclusively express 
VPAC1-R and VPAC2-R (Vaccari et al., 2006). PAC1-
R was the main receptor present in the ovary of rats, 
followed by VPAC2-R and VPAC1-R (Lat ini et al., 
2010).  
 
Signaling pathways and effects of VIP on follicle 
survival  
 
VIP has been shown to protect several cell 
types from apoptosis, including thymocytes, prostate 
cancer and neural cells (Delgado et al., 1996; Said, 
1996; Gutierrez-Canas et al., 2003; Sastry et al., 2006). 
In the ovary, previous in vitro studies also demonstrated 
that VIP inhibits apoptosis of rat follicles (Flaws et al., 
1995; Lee et al., 1999). Moreover, it has been 
demonstrated that PACAP and VIP were able to prevent 
granulosa cell apoptosis of follicles cultured in serum 
free medium (Vaccari et al., 2006; Barberi et al., 2007). 
Morelli et al. (2008) have shown that VPAC1-R and 
VPAC2-R mRNAs were induced by gonadotropin 
stimulat ion and the apoptotic effect of serum 
withdrawal from human granulosa-luteal cells culture 
was reverted by both PACAP and VIP. Both peptides 
showed the ability to reverse a decrease in procaspase-3 
levels induced by culture in the absence of serum. 
Recently, VIP maintained the ultrastructural integrity of 
goat preantral follicles after seven days of ovarian tissue 
culture (Bruno et al., 2010). 
It is possible that VIP maintains cell viability 
through the cAMP pathway. The stimulation of cAMP 
formation by VIP is probably a transient response that 
occurs early after culture in itiation. In support of this, 
the ability of VIP to suppress apoptosis was mimicked 
by treatment of follicles with the adenylyl cyclase 
activator (forskolin), and this substance increased 
cAMP production and accumulation within cultured 
follicles (Flaws et al., 1995). These findings, along with 
previous reports on the role of the cAMP-protein kinase 
A (PKA) second messenger system in mediating the 
effects of VIP in target cells (Davoren and Hsueh, 1985; 
Johnson and Tilly, 1988; Ojeda et al., 1989), provide 
evidence that VIP, potentially acting at least in part v ia 
the cAMP pathway, functions as a novel inhibitor of 
apoptosis.  
Studies have shown that the neuroprotective 
effects of VIP are mediated partially via activation of 
PKA through PKC (Vaudry et al., 2000) and cAMP-
response element (CRE) binding protein (CREB) 
phosphorylation (Walton and Dragunow, 2000). The 
effect or mechanis ms include inhibit ion of caspase-3 
activity, upregulation of Bcl-2 and suppression of 
cytoplasmic cytochrome c translocation (reviewed by 
Filippatos et al., 2001). Moreover, VIP activates 
mitogen-activated protein kinase (MAPK) cascade 
through the PKA pathway in the GH4C1 rat pituitary 
cell line (Le Péchon-Vallée et al., 2000). Fernández et 
al. (2003) have shown previously that VIP-induced 
lactotroph proliferat ion is mediated by cAMP/PKA and 
MAPK signaling pathways. Studies have provided new 
insights into cAMP signal transduction and 
demonstrated that Rap1 can p lay a crucial ro le in 
mediating cAMP-induced MAPK activation in specific 
cell types (Vossler et al., 1997, Alleaume et  al., 2003). 
These studies have shown that cAMP can stimulate 
Rap1 activation, leading to activation of B-Raf, 
MAPK/extracellu lar signal regulated kinase (ERK) 
kinase 1 (MEK1) and MAPK. More recently, Fernández 
et al. (2005) demonstrated that VIP-dependent 
activation of the ERK signaling pathway in GH4C1 
cells requires the PKA-Rap1 pathway (Fernández et al., 
2005).  
Conversely, it is plausible that mechanisms 
independent of PKA activity also partly mediate the 
actions of VIP on follicle survival. This possibility is 
supported by previous studies using a mouse pituitary 
cell line that demonstrated activation of voltage-
sensitive calcium channels after VIP stimulation 
(Schecterson and McKnight, 1991). In this work, β-
endorphin secretion by cells in response to VIP was
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inhibited in the presence of Ca2+ chelator EGTA, in the 
absence of extracellu lar Ca2+, or when Ca2+ channels 
were blocked. Based on these results, VIP appears to 
activate a voltage-sensitive Ca2+ channel which allows 
the influx of ext racellular Ca2+ required to stimulate β-
endorphin secretion. Several peptide hormones have 
more than one type of receptor, and these receptor 
subtypes can be coupled to completely different 
intracellular message systems. Malhotra et al. (1988) 
demonstrated that VIP mobilizes intracellu lar Ca2+ via 
inositol triphosphate generation to induce catecholamine 
secretion in the adrenal medulla, indicating that other 
signal transduction mechanisms are coupled to VIP 
receptors. Also, VIP has been shown to alter several 
voltage-sensitive conductances in GH3/B6 pituitary 
cells, and only part of these actions is mimicked by 8-
bromo-aAMP (Hedlund et al., 1988).  
 
In vitro effects of VIP on follicle growth 
 
There are only a few papers dealing with VIP 
effects on the ovarian follicles. In vitro studies revealed 
that VIP stimulates the development of isolated bovine 
primary and early secondary follicles (Hulshof, 1995). 
We have recently demonstrated that VIP is an important 
factor for the growth of small preantral follicles 
enclosed in caprine ovarian tissue (Bruno et al., 2010). 
In addition to the increase of VIP immunoreactivity 
with the appearance of secondary and antral fo llicles in 
bovine ovaries (Hulshof et al., 1994), the contemporary 
presence of VIP and its receptors around preantral and 
antral follicles (Vaccari et al., 2006) may explain the 
role of VIP in fo llicle growth. Nevertheless, in mice, 
VIP did not affect follicular development and caused 
inhibit ion of follicular growth, antrum format ion, 
granulosa cell proliferation, as well as estradiol 
production of follicles stimulated by FSH (Cecconi et 
al., 2004). These conflict ing results may be due to study 
design, differences related to species, culture conditions 
and different fo llicular stages analyzed. 
 
Influence of VIP on maturation and ovulation 
 
Studies have shown that VIP stimulates 
maturation in fo llicle-enclosed oocytes, but could 
transiently inhibit or not affect spontaneous maturation 
of cumulus-enclosed oocytes (Tornell et al., 1988; Apa 
et al., 1997). Culture of bovine cumulus oocyte 
complexes in the presence of VIP did not affect nuclear 
maturation or cumulus expansion, but it retarded 
cytoplasmic maturat ion as reflected by delayed cortical 
granule migration (Beker et al., 2000). Moreover, the 
addition of VIP to the culture medium did  not improve 
in vitro maturation and fertilization of sheep (Ledda et 
al., 1996) and buffalo (Nandi et al., 2003) oocytes.  
Two possible explanations for the limited 
response to VIP in events of maturation can be 
suggested: first, depending on the experimental 
conditions, cAMP can either stimulate or inhib it meiosis 
(Hillensjo et al., 1978). It is possible that high doses of 
VIP sustain high levels of cAMP in the oocyte and 
prevent meiosis. Such a phenomenon is believed to 
occur in the presence of forskolin (Ekholm et al., 1984), 
dbcAMP, or phosphodiesterase inhibitors (Hillensjo et 
al., 1978). A second exp lanation for the limited 
response could be that VIP affects only one 
subpopulation of follicles or subpopulation of granulosa 
cells within each follicle. In fact, Kasson et al. (1985) 
have shown one predominantly VIP-sensitive and one 
FSH-sensitive subpopulation of granulosa cells.  
Nevertheless, although VIP did not influence 
maturation, Hulshof et al. (1994) observed that VIP-
containing cells were found exclusively in the granulosa 
layer of the preovulatory follicle around the time of the 
LH peak. Th is suggests a role of VIP in the final stage 
of follicle development. Indeed, VIP has been shown to 
stimulate ovulation in perfused rat ovaries (Schmidt et 
al., 1990). In the mammalian system, VIP or LH, acting 
via the adenylyl cyclase system, induce an increase in 
plasminogen activator activity (Beers, 1975; Wang and 
Leung, 1983; Liu et al., 1987), a serine protease that has 
been implicated in the process of follicular rupture at 
the time of ovulation (Beers, 1975; Reich et al., 1985) 
and in the process of follicular cumulus cell expansion 
and dispersion (Liu et al., 1986).  
In addition, the localizat ion of VIP and its 
receptors in association with blood vessels (Hulshof et 
al., 1994; Vaccari et al., 2006) suggests that this 
neuropeptide might be involved in the regulation of 
ovarian blood flow. In fact, VIP contributes to the 
increase in blood flow around preovulatory follicles 
observed after the LH surge (Acosta et al., 2003). This 
increased ovarian stromal blood flow may, in turn, lead 
to a greater delivery of gonadotropins to the granulosa 
cells of preovulatory follicles (Redmer and Reynolds, 
1996), which will be important for the generation of a 
normal follicle and competent oocyte. The gonadotropins 
would consequently stimulate the production of PACAP in 
the preovulatory follicle. The fact that PACAP induces 
genes related to ovulation and luteinization, and mediates 
some of the effects of LH on granulosa cell differentiation 
at the time of ovulation (Gras et al., 1999; Lee et al., 1999, 
Park et al., 2000), suggests that PACAP may serve as an 
ovarian physiological mediator of gonadotropins in the 
ovulatory process. This is in agreement with a previous 
demonstration that provides direct evidence of the 
presence of PAC1-R and the absence of VPAC1-R and 
VPAC2-R on germinal vesicles oocytes (Vaccari et al., 
2006). Further studies are warranted to evaluate the 
respective roles of PACAP and VIP in ovulatory 
process. 
 
VIP stimulates ovarian steroidogenesis 
 
Studies have shown that in the periphery, the 
denervation of ovaries during the early luteal phase of
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the estrous cycle leads to changes in their morphology 
and impairs steroidogenic activity in pigs (Jana et al., 
2005). Similarly, inhib ition of ovarian secretory 
function and delayed pubertal onset were observed in 
rats after denervation (Ojeda et al., 1983; Lara et al., 
1990; Forneris and Aguado, 2002). The alterat ions in 
gonadal endocrine function are attributed to the loss of 
the peptidergic supply (for example, VIP) of neuronal 
fibers (Ojeda et al., 1983; Lara et al., 1990; Forneris et 
al., 2002; Jana et al., 2005). Therefore, these studies 
show that VIP is implicated in ovarian steroidogenesis. 
In addition, VIP is involved in the regulation of 
steroidogenic activity, stimulating estradiol and 
progesterone release from cultured granulosa cells and 
whole ovaries in vitro (Davoren and Hsueh, 1985; 
Ahmed et al., 1986; Parra et al., 2007; Kowalewski et 
al., 2010), progesterone release in vivo (Fredericks et 
al., 1983), and androgen release from ovarian fragments 
in vitro (Ahmed et al., 1986). These effects may be 
related to the ability of VIP to enhance the synthesis of 
the cholesterol side-chain cleavage enzyme complex 
(Trzeciak et al., 1986), the rate-limit ing step in 
progesterone biosynthesis and the activity of the 
aromatase enzyme complex (George and Ojeda, 1987). 
Studies have provided evidence that VIP is capable of 
inducing aromatase activity before the ovary became 
responsive to gonadotropins (George and Ojeda, 1987; 
Mayerhofer et al., 1997). A possibility to consider is 
that VIP induction of estradiol release during the estrous 
cycle may also come from immature follicles. If true, 
this would suggest that VIP p lays a complementary role 
to that of FSH, the primary mediator of estradiol 
biosynthesis, in determining the magnitude of estradiol 
increase under varying physiologic conditions (Parra et 
al., 2007). These findings suggest a role for this peptide 
in ovarian steroid biosynthesis.  
Little is known about the molecular 
mechanis ms of VIP-mediated steroidogenesis. It is 
known that VIP increases the levels of cAMP (Tornell 
et al., 1988, Apa et al., 1997;  Vaccari et al., 2006) and 
subsequently leads to PKA activation, which in turn 
induces steroidogenesis in granulosa cells. The 
cAMP/PKA pathway is the major route in the trophic 
hormone-stimulated regulat ion of steroidogenic acute 
regulatory protein (StAR) expression and function. The 
activation of PKC has been shown to result in the 
effective transcription and translation of StAR. 
However, a fu rther activation of the PKA pathway is 
required to effectively phosphorylate StAR and induce 
steroid production (Jo et al., 2005). On the basis of this 
phenomenon, using specific analogs of cAMP to 
preferentially activate either type I or type II PKA, 
Dyson et al. (2009) were ab le to show that type I PKA 
is more involved in StAR gene expression, while the 
activation of type II PKA is essential for efficient 
phosphorylation of StAR and consequently production 
of steroids. Indeed, Kowalewski et al. (2010) observed 
that VIP together with cAMP-analogs that activate Type 
II PKA increased P-STAR and further increased 
steroidogenesis. StAR mediates the rate-limit ing step in 
steroidogenesis, the transfer of cholesterol from the 
outer to the inner mitochondrial membrane, and it is the 
hormonal regulat ion of StAR expression and activity 
that allows tissues to accurately control their steroid 
production (Kowalewski et al., 2010). A reduction of 
StAR and 3β-hydroxysteroid dehydrogenase expression, 
enzyme converting pregnenolone to progesterone, 
accompanied by decreased serum levels of FSH was 
demonstrated in young VIP knockout mice (Lacombe et 
al., 2007). Additional signaling pathways may be involved 
because the receptors activate multiple intracellular 




Collectively, these results suggest the role of 
VIP and its receptors in the control of ovarian 
follicu logenesis. VIP and its receptors, mostly through 
cAMP/PKA pathway regulate the follicle survival and 
growth, oocyte maturation and ovulation, as well as 
ovarian steroidogenesis. Further research in this field 
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